Aldawsari Hibah M, Singh Sima
Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Discipline of Pharmaceutical Sciences, College of Health Sciences, University of KwaZulu Natal, Durban X54000, South Africa.
Nanomaterials (Basel). 2020 Mar 11;10(3):510. doi: 10.3390/nano10030510.
Cisplatin is one of the most leading potent chemotherapy drugs prescribed for the treatment of most solid tumors. However, the induction of toxicities and the development of resistance restricts its applications. Efforts are made in the proposed study to control the delivery of cisplatin to tumor sites by incorporating it into solid lipid nanoparticle (SLNs) drug carriers. By considering this fact, in the current research work, a single-step, one-pot, microwave-assisted technology was used to produce cisplatin-loaded SLNs. The shape of the SLNs was observed to be spherical, with a uniform size distribution of 74.85 nm, polydispersity index (PDI) of 0.311, and zeta potential of -20.8 mV. The percentage of encapsulation efficiency was found to be 71.85%. drug release study was calculated to be 80% in 24 h. The formulation in blood was found to be safe; a study of hemolysis confirmed this. Breast cancer cell line MCF-7 was used to test cytotoxicity and cellular interaction of cisplatin-loaded SLNs with an IC value of 6.51 ± 0.39 μg/mL. Overall, the results of our findings show that the approach of SLNs-based, cisplatin-based, drug delivery has led to increased sustainability in breast cancer therapy with superior biocompatibility.
顺铂是治疗大多数实体瘤最常用的强效化疗药物之一。然而，毒性的产生和耐药性的发展限制了其应用。本研究通过将顺铂纳入固体脂质纳米粒（SLNs）药物载体来控制其向肿瘤部位的递送。考虑到这一事实，在当前的研究工作中，采用了单步、一锅法、微波辅助技术来制备载顺铂的SLNs。观察到SLNs的形状为球形，平均粒径为74.85 nm，粒径分布均匀，多分散指数（PDI）为0.311，zeta电位为-20.8 mV。包封率为71.85%。药物释放研究表明，24小时内药物释放率为80%。血液中的制剂被发现是安全的；溶血研究证实了这一点。使用乳腺癌细胞系MCF-7测试载顺铂SLNs的细胞毒性和细胞相互作用，IC值为6.51±0.39μg/mL。总体而言，我们的研究结果表明，基于SLNs和顺铂的药物递送方法提高了乳腺癌治疗的可持续性，并具有优异的生物相容性。
